We are live on ! Find out more
STAB

Statera Biopharma, Inc. Common Stock
STAB

Delisted

STAB was delisted on the 11th of January, 2023.

Back to rankings

17 hedge funds and large institutions have $679K invested in Statera Biopharma, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

181% more capital invested

Capital invested by funds: $242K → $679K (+$437K)

21% more funds holding

Funds holding: 14 → 17 (+3)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

Holders
17
Holders Change
+3
Holders Change %
+21.43%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$36K
2
WS
Wedbush Securities
California
+$27.2K
3
Citadel Advisors
Citadel Advisors
Florida
+$24.5K
4
Victory Capital Management
Victory Capital Management
Texas
+$2.88K
5
BRWA
B. Riley Wealth Advisors
Florida
+$2.35K

Top Sellers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
-$43.2K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$8K
3
Bank of America
Bank of America
North Carolina
-$6.26K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$10
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
1
Renaissance Technologies
New York
$480K -$43.2K -21,165 -7%
Vanguard Group
2
Vanguard Group
Pennsylvania
$88K +$36K +17,639 +50%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$29K – – –
BRWA
4
B. Riley Wealth Advisors
Florida
$29K +$2.35K +1,150 +7%
WS
5
Wedbush Securities
California
$22K +$27.2K +13,321 New
Citadel Advisors
6
Citadel Advisors
Florida
$20K +$24.5K +12,009 New
Royal Bank of Canada
7
Royal Bank of Canada
Ontario, Canada
$6K -$10 -5 -0.1%
Carson Wealth (CWM LLC)
8
Carson Wealth (CWM LLC)
Nebraska
$2K – – –
Victory Capital Management
9
Victory Capital Management
Texas
$2K +$2.88K +1,410 New
BlackRock
10
BlackRock
New York
$1K – – –
FDCDDQ
11
Federation des caisses Desjardins du Quebec
Quebec, Canada
$166 +$204 +100 New
Susquehanna International Group
12
Susquehanna International Group
Pennsylvania
– -$8K -13,922 Closed
Bank of America
13
Bank of America
North Carolina
– -$6.26K -3,068 -97%
Wells Fargo
14
Wells Fargo
California
– +$65 +32 New
Morgan Stanley
15
Morgan Stanley
New York
– +$204 +100 New
Osaic Holdings
16
Osaic Holdings
Arizona
– +$592 +290 New

STAB Hedge Fund Activity: Q1 2020 in Review

17 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q1 2020, worth a combined $679K — up 181% from $242K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new STAB positions and 2 closed out — a net gain of 5 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, adding an estimated $36K. The largest seller was Renaissance Technologies, cutting an estimated $43.2K.

  • 17 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q1 2020, up from 14 in Q4 2019.
  • Funds reported $679K of Statera Biopharma, Inc. Common Stock stock for Q1 2020, up 181% quarter-over-quarter.
  • 7 funds opened new Statera Biopharma, Inc. Common Stock positions in Q1 2020 and 2 closed out, a net change of +5 holders.
  • The largest Statera Biopharma, Inc. Common Stock buyer in Q1 2020 was Vanguard Group, an estimated $36K added.
  • The largest Statera Biopharma, Inc. Common Stock seller in Q1 2020 was Renaissance Technologies, an estimated $43.2K sold.

Based on aggregated 13F filings for Q1 2020.